CDRD, University of Ottawa sign affiliation agreement for drug development platform The University of Ottawa and the Centre for Drug Research and Development today announced that they have signed an affiliation agreement that may allow researchers at the University of Ottawa to gain access to CDRD’s drug development infrastructure and expertise. ‘We are very happy to set up this affiliation contract with CDRD,’ stated Joe Irvine, Director, Technology Transfer and Business Enterprise . ‘This collaboration provides us with access to specialized facilities and experience at CDRD that may act as a catalyst for developing University of Ottawa study innovations into new scientific therapies. Solid partnerships promote development, and CDRD has established a unique ability in Canada for advancing medical invention.’ ‘CDRD is very happy to broaden our network of affiliate marketer organizations to the University of Ottawa, and looks ahead to working with their talented researchers.21 issue of the journal Proceedings of the National Academy of Sciences by researchers at Cerus Corp. In Concord, Calif., employs a genetically engineered listeria bacteria predicated on a strain created by University and coauthor of California, Berkeley, microbiologist Daniel Portnoy. Buoyed by the success of the new cancer vaccine, Cerus researchers are aiming for human trials now. Cerus eventually hopes to utilize the genetically built listeria vaccine to target cancers such as for example ovarian and pancreatic cancers, and leukemia and different solid tumors possibly.